WO2005054451A1 - 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター - Google Patents
高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター Download PDFInfo
- Publication number
- WO2005054451A1 WO2005054451A1 PCT/JP2003/015632 JP0315632W WO2005054451A1 WO 2005054451 A1 WO2005054451 A1 WO 2005054451A1 JP 0315632 W JP0315632 W JP 0315632W WO 2005054451 A1 WO2005054451 A1 WO 2005054451A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- virus
- vaccinia virus
- strain
- promoter
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to novel vaccinia viruses and viral vectors. Specifically, reversion (reverted mutation or ancestral return) is caused. Attenuated pressure ulcer vaccinia virus LC 16m8 strain, and its parental LC 1 6mO strain is removed. Thus, the present invention relates to a genetically stable and safer Vaccinia virus / vaccinia virus vector that is less susceptible to reversion. Background art
- LC16 LC16m0 strain (hereinafter sometimes referred to as the m0 strain) that formed a smaller box was selected.
- the mO strain was inoculated to about 1000 people. However, the mO strain still had a strong reaction on the skin.
- the LC 16m8 strain (hereinafter sometimes referred to as the m8 strain) was established as a small box size strain (Hiroshi Hashizume, Clinical and Virus Vo. 3 No. 3, July 1, 1975).
- the m8 strain was inoculated to 100,000 children from 1974 to 1975, but no serious adverse reactions were reported, which proved to be highly safe compared to conventional vaccine strains. It was approved by the Ministry of Health and Welfare as an official vaccine strain.
- the m8 strain had a weak skin growth ability, the antibody induction ability was almost the same as that of the parent Lister strain, and the safety was clearly superior.
- This strain was also greatly improved in that it could be produced by aseptic tissue culture using primary cultured cells of the rabbit kidney.
- vaccinia virus has been used as a vector by introducing other foreign genes because it has a wide host range and high expression efficiency (Japanese Patent Publication No. 1-509091).
- Japanese Patent Publication No. 1-509091 Japanese Patent Publication No. 1-509091.
- the aforementioned LC 16m0 and LC 16m8 strains were also considered for use as vectors because of their high safety.
- the LC 16m0 strain has a problem in terms of skin growth
- the LC 16m8 strain has a problem of the appearance of revertants, so it is safer as a pressure ulcer vaccine strain or vector virus. It was necessary to create a virus strain with a high level. Disclosure of the invention
- An object of the present invention is to produce a vaccine strain that is unlikely to cause reversion (an ancestor return), and to provide a safer pressure ulcer vaccine. Further It is another object of the present invention to provide a vector virus for safely expressing a foreign gene using the virus.
- the gene involved in reversion is a B5R gene that resembles the virus host castle and plaque size.
- the B5R gene inactivated due to the loss of most of the orf due to a frame shift due to a single base deletion in or f, but in the repartant, a base is newly inserted at another location.
- Figures 1 and 2 The base sequence of the B5R gene is shown in SEQ ID NO: 1, and the amino acid sequence of the B5R gene product is shown in SEQ ID NO: 2.
- the ori of the B5R gene is complete.
- the B5R gene of the mO strain was first cloned and introduced into the m8 strain by homologous recombination to produce a recombinant virus (RVV) with the complete B5R gene (m8B5R).
- RVV recombinant virus
- This RVV screening was performed by selecting large plaques and then sequencing the B5R gene.
- constructs were constructed that completely deleted the entire B5R gene, including the promo and overnight regions (AB5R, Fig. 6). By homologous recombination, the B5R gene was deleted in the m8B5R and mO strains.
- RVV m8AB5R (hereinafter also referred to as ⁇ 8 ⁇ ) and mOAB5R (hereinafter also referred to as ⁇ ⁇ )) were introduced. Furthermore, the transmembrane region of the B5R gene was removed, and a construct linked to the high expression promoter PSFJ 1-10 was created (proB5RdTM, Fig. 6). M0proB5 dTM (hereinafter sometimes referred to as mOdTM))). RVV screening was done by selecting small plaques and confirming the genomic sequence.
- ni8AB5R, mOAB5R, m8proB5RdTM and m0proB5RdTM have higher genetic stability than the m8 strain.
- the present invention is as follows.
- Vaccinia virus strain Vaccinia virus strain that consists of vaccinia virus that does not produce B5R gene product with normal function, lacking part or all of B5R gene of LC16 strain, LC16m8 strain or LC16m0 strain Pressure ulcer vaccine virus that is less prone to back mutations that cause the production of B5R gene products with normal function,
- a promoter is linked upstream of the B5R gene, and a part of the B5R gene is expressed, but the expression product has lost the normal function of the B5R gene expression product, [8]
- a pressure ulcer vaccine pharmaceutical composition comprising the pressure ulcer vaccine virus according to any one of [1] to [1 0],
- a vaccinia virus vector that lacks part or all of the B5R gene of the vaccinia virus strain LC16, LC16m8 or LC16mO and does not produce a normal B5R gene product.
- Vaccinia virus vector according to any one of [1 2] to [1 4], in which plaque size when infected with rabbit kidney cells and subcutaneous growth when administered to rabbits is equivalent to LC16m8 strain ,
- a part of the B5R gene is deleted, a promoter is linked upstream of the B5R gene, and a part of the B5R gene is expressed.
- [1 7] A vaccinia virus vector according to any one of [1 2] to [1 6], wherein the transmembrane domain of the B5R gene is deleted,
- a promoter is linked upstream of the B5R gene, and a part of the B5R gene is expressed, but the expression product loses the normal function of the B5R gene expression product, [1 9] vaccinia virus vector,
- [2 1] The vaccinia virus vector of [1 9] or [2 0], wherein the promoter is PSFn-10, PSFJ2-16 or other box virus high expression promoter,
- [2 2] A vaccinia virus vector according to any one of [1 2] Kas et al. [2 1] containing a foreign gene,
- a virus virus, bacterial, protozoan or cancer vaccine virus pharmaceutical composition comprising the vaccinia virus vector according to [2 3].
- FIG. 1 is a diagram showing the base sequences of the B5R gene of the liver of the LC16mO strain, the LC16m8 strain and the LC16m8 strain.
- FIG. 2 is a diagram showing the amino acid sequences of the B5R gene products of Lipper Yun of LC16mO, LC16m8 and LC16m8 strains.
- FIG. 3 shows the passage from Lister strain to LC16m8.
- FIG. 4 shows the characteristics of the Lister strain, LC16mO strain and LC16m8 strain.
- Figure 5 shows LPC (Large Plaque), the LC16m8 and LC16m8 strain revertants.
- FIG. 6 is a conceptual diagram of a method for constructing a virus lacking the B5R gene.
- FIG. 7 is a photograph showing the results of confirming the expression of B5R protein in the RK13 cell fraction infected with the improved virus using a Western plot.
- FIG. 8 is a graph showing the frequency of appearance of ribartan silkworms by subculture of the improved virus.
- FIG. 9 is a diagram showing the skin growth of the improved virus in rabbits.
- FIG. 1 OA shows the weight loss of SCID mice administered with virus.
- FIG. 10B is a graph showing weight loss of SCID mice administered with virus.
- FIG. 11 shows changes in RED50 over time in SCID mice administered with virus.
- Figure 12 shows the weight loss of BALB / c mice challenged with virulent vaccinia virus.
- the vaccinia virus of the present invention can be produced by deleting all or part of the B5R gene of vaccinia virus, for example, LC16 strain, LC16niO strain or LC16m8 strain.
- the B5R gene encodes a protein present in the envelope, and the B5R gene product is involved in viral infection.
- the presence of the B5R gene has a problem in that it has a high skin proliferative potential and causes side effects such as self-inoculation when administered to humans.
- the LC16m8 strain did not produce the B5R gene product due to a single-base frameshift mutation in the B5R gene, and the skin growth was weak, but the reverse mutation produced a normal B5R gene product. (Reversion), there was a risk that pathogenicity could be restored.
- the vaccinia virus of the present invention lacks all or part of the B5R gene.
- the pathogenicity originally possessed by the parent LC16mO strain is reduced, and in the m8AB5R, revertants are not generated by the sudden reversion of the parent LC16in8 strain.
- the deletion of the B5R gene in the present invention is such that the B5R gene is not expressed or is expressed but the expressed protein does not maintain the normal function of the B5R gene product.
- This deletion is not such that the trait is restored by a point mutation of the virus, but the normal function of the B5R gene product once lost is not restored.
- one of the bases of the B5R gene was deleted due to a mutation, resulting in a frameshift, the 0RF of the B5R gene was shifted, and normal B5R was not expressed.
- 0RF of the B5R gene is restored, and B5R with normal function is expressed, causing an ancestral return.
- Deletions of the present invention do not include deletions that can cause ancestral return by such i3 ⁇ 4 mutations.
- the B5R gene consists of a short consensus region from SCR1 to SCR4 and a transmembrane domain (TM), and the transmembrane domain plays an important role in the function of the B5R gene product.
- the deletion of the B5R gene may be a deletion of the transmembrane domain.
- a part of SCR1 to SCR4 may be deleted.
- the deletion may be all deletions of ⁇ A encoding each region, or a part of the DNA encoding each region may be deleted to produce a B5R gene product with normal function.
- the deletion of the B5R gene is a deletion of all B5R genes or a deletion of all transmembrane domains. It is also desirable to delete the B5R gene promoter. Such deletion can be performed by a known homologous recombination method.
- Homologous recombination is a phenomenon in which two DNA molecules have the same base sequence in a cell and cause recombination with each other. This method is often used for recombination of viruses with large genomic DNA such as vaccinia virus. .
- target A plasmid which is called a transfer vector
- a transfer vector linking a gene and a foreign gene is constructed in such a way that the sequence of the vaccinia virus gene site is divided at the center, and this is applied to cells infected with vaccinia virus.
- replacement occurs between the viral DNA that became naked during the viral replication process and the same sequence on the transfer vector, and the sandwiched promoter and foreign gene are integrated into the viral genome.
- a vaccinia virus B4R gene to B6R gene region was cloned into a plasmid, and the entire B5R gene region located between the B4R gene and the B6R gene was deleted.
- a plasmid in which a part of the B5R gene is deleted is prepared and introduced into vaccinia virus-infected cells.
- the cells include BSC-1 cells, HTK-143 cells, Hep2 cells, MDCK cells, Vero cells, HeLa cells, CV1 cells, COS cells, RK13 cells, BHK-21 cells, primary rabbit heron kidney cells Cells that can be infected by an isozyme virus can be used.
- the vector may be introduced into the cells by a known method such as a calcium phosphate method, a cationic ribosome method, or an electroporation method.
- genes that can be selected markers eg, B5R gene, HA gene, TK gene, etc.
- a transfer vector can be designed based on the nucleotide sequence information of the vaccinia virus gene, and then the gene to be disrupted can be homologously recombined using the transfer vector.
- the transfer vector can be prepared according to the method described in DM Globe et al., Edited by Tomoyuki Kato, DNA Cloning 4 Mammal System 1 (2nd edition) TaKaRa et al.
- plaque size in the case of B 5R gene
- HA gene presence or absence of plaque erythrocyte adsorption
- TK BudR drug resistance
- a selection method such as gene
- the B5R gene product is present on the infected cell surface and on the viral envelope, and acts to increase the efficiency of infection when the virus infects and spreads to neighboring cells or other parts of the host, and increases the virus plaque size and It is also involved in the host range.
- the plaque size is reduced when animal cells such as RK 13 cells are infected, and the box size on the chorioallantoic membrane of embryonated chicken eggs is also reduced.
- virus growth in Vero cells is significantly reduced.
- the ability of the skin to proliferate when administered intradermally to Usagi is reduced and skin pathogenicity is reduced.
- the lack of B5R protein function depends on the size of plaque formed when RK13 cells are infected, box size, virus propagation in Vero cells, skin pathogenicity in rabbits, etc. It can be judged as an indicator.
- the gene sequence of vaccinia virus may be examined.
- the silkworm virus of the present invention has a smaller plaque size when infected with animal cells, a smaller pock size, and a virus in Vero cells. Proliferation, dermatopathogenicity, etc. have also decreased, compared to the LC 16m8 strain, the black size and box size when animal cells are infected are the same.
- Virus growth in cells and subcutaneous pathogenicity are equivalent.
- Fig. 5 shows the plaque size when the LC 16mO and LC 16m8 strains were infected with rabbit kidney cells
- Fig. 9 shows the skin growth in the rabbits of the LC 16mO and LC 16m8 strains (the recloned LC 16m8 strain).
- deletion of the B5R gene also reduces virulence when inoculated into animals. For example, when the virus is inoculated intraperitoneally into a SC ID mouse and the body weight is measured over time, a virus strain that produces a B5R gene product with normal function is inoculated with 10 5 PFU virus for 2 weeks.
- the B5R gene product having a normal function in the present invention is a gene product having the same function as that of the gene product encoded by the wild-type B5R gene, and has the above properties.
- the infection defense was comparable to the virus strain with the B5R gene (Fig. 12), but the B5R gene product is Because it has been reported that it is important as an anti-infection protective antigen, it may be desirable that a part of the B5R gene product is produced when used as a pressure ulcer vaccine. Therefore, in the vaccinia virus of the present invention, the B5R gene should be expressed in a form in which normal function is lost while maintaining the antigenicity of the actual product. For this purpose, the virus should be designed so that only a part of the B5R gene, for example, a part or all of SCR1 to 4 is expressed.
- a high-expression promoter may be linked to the upstream of the partially deleted B5R gene so as to function.
- psFn-10, PSFJ2-16, p7.5K promoter, P11K promoter, T7.10 promoter, CPX promoter, HF promoter, H6 promoter, T7 hybrid promoter, etc. A high expression promoter for Pokpox virus.
- the LC16mO strain and the LC16m8 strain that have completely deleted the B5R gene are referred to as m0AB5R and m8AB5R, respectively, and are sometimes referred to as ⁇ and ⁇ 8 ⁇ , respectively, and the transmembrane domain in the B5R gene is deleted.
- the LC16mO and LC16m8 strains, which are highly expressed by linking promo overnight, are called mOproBSRdTM and m8proB5RdTM, respectively, and are called m0dTM and m8dTM, respectively. There is.
- the LC16mO strain was produced from the Lister strain via the LC16 strain, and the LC16m8 strain was further produced from the LC16mO strain (Protein Nucleic Acid Enzyme Vol.48 No.12 (2003), p.1693- 1700). Isolation of the LC 16m8 strain from the Lister strain is carried out by the process shown in FIG. 2, and the LC16m0 strain and the LC16m8 strain can be obtained from Chiba Prefectural Institute of Public Health.
- the LC16m0 and LC16m8 strains lacking the B5R gene of the present invention can be used as safe pressure ulcer virus vaccines without causing reversion.
- the present invention also includes a vaccinia virus vector comprising the LC16 strain, the LC16m0 strain, and the LC16m8 strain that lack the B5R gene.
- a desired foreign gene can be introduced into the vector.
- Homologous recombination may be performed by the method described above. For example, a plasmid (transfer vector) in which a foreign gene to be introduced is linked into the DNA sequence of the site to be introduced is prepared, and this is introduced into a cell infected with vaccinia virus.
- pSFJl-10, pSFJ2-16, P ⁇ 4, pGS20, pSClK pMJ60K p200K pBCB01-3, 06, pTKgpt-F 1-3s, pTMK pTM3, pPR34, 35, pgpt-ATA18_2, pHESl-3 Etc. can be used.
- the introduction region of the exogenous gene is a gene that is not essential for the life cycle of ⁇ cinnavirus, and examples include hemagglutinin (HA) gene, thymidine kinase (TIO gene, F fragment, etc.).
- the gene to be introduced changes to a viral trait due to its deletion, facilitating selection of recombinants
- the HA gene in the case of a recombinant in which a foreign gene is introduced into the HA gene, it is disrupted by the foreign gene into which the HA gene has been introduced and loses its function. Recombinants can be easily selected because they no longer adsorb avian red blood cells and appear white.
- the vaccinia virus-infected cells include: Velo cells, HeLa cells, CV 1 cells, COS cells, RK 13 cells, BHK-2 1 cells, primary rabbit kidney cells, B SC-1 cells, HTK-143 cells, Hep2 Cells capable of infecting vaccinia virus, such as cells and MDCK cells, can be used.
- the promoters include, but are not limited to, PSF JH-10, PSFJ 2-16, p7.5K promoter, pl lK promoter motor, T7.10 promoter, CPX promoter, HF promoter, H6 promoter, T7 hybrid.
- the foreign gene can be produced using a vaccinia virus vector into which the foreign gene has been introduced.
- the host cell may be cultured by infecting a suitable host cell with a vaccinia virus vector introduced with a foreign gene.
- the various animal cells described above can be used as the host cell.
- the culture may be performed according to known culture conditions for animal cells.
- by introducing genes encoding antigens such as viruses, bacteria, protozoa, and cancer as foreign genes it is possible to use silkworm virus vectors introduced with foreign genes as vaccines against various viruses, bacteria, protozoa, and cancer. it can.
- human immunodeficiency virus hepatitis virus, herpes virus, mycobacteria, malaria parasite, serious acute respiratory syndrome (SARS virus) virus and other protective antigens (neutralizing antigens) or cancer antigens are encoded.
- a gene may be introduced.
- the present invention also includes a vaccinia virus vector into which these antigens have been introduced.
- the present invention relates to a pharmaceutical composition for a pressure ulcer vaccine comprising a vaccinia virus deleted of the B5R gene of the present invention, the use of the vaccinia virus deleted of the B5R gene of the present invention as a pressure ulcer vaccine, and a vaccinia virus as a subject. And a method of protecting against smallpox infection.
- the administration method, dosage and the like of the vaccine pharmaceutical composition of the present invention are the same as those of the known vaccinia virus vaccine already used as a vaccine.
- the vaccine pharmaceutical composition of the present invention is a pharmaceutically effective amount of the present invention.
- vaccinia virus vaccine as an active ingredient, and may be in the form of a sterile aqueous or non-aqueous solution, suspension, or emulsion. Further, it may contain a pharmaceutically acceptable diluent such as salt, buffer, adjuvant, etc., an auxiliary agent, a carrier and the like.
- Administration of the vaccine pharmaceutical composition of the present invention may be performed by various parenteral routes, for example, subcutaneous route, intravenous route, intradermal route, intramuscular route, intraperitoneal route, intranasal route, and transdermal route. Of these, intradermal administration is preferred.
- a pharmaceutically effective dose is an amount that is sufficient to obtain at least one of the desired biological effects, in this case a cellular or humoral immune response to a viral antigen.
- the effective dose can be appropriately determined according to the age, sex, health, weight, etc. of the subject. For example, but not limited to adult humans, approximately 10 2 to 10 1 G box forming units (PFU) or plaque forming units (PFU), preferably 10 5 to 10 6 box forming units (PFU) per dose.
- the present invention provides a vaccinia virus vaccine drug that is a vaccinia virus vector in which a B5R gene is deleted and a foreign gene is introduced, wherein the introduced foreign gene encodes a virus, bacteria, protozoa, or cancer antigen.
- the administration method and dosage of the vaccine pharmaceutical composition may be in accordance with the above-described pressure ulcer vaccine pharmaceutical composition.
- the purified genomic DNA of the m8 strain is used as a saddle type, and the B4R gene is amplified by two primers (GATGCTGTTGTGCTGTGTTTGC (SEQ ID NO: 3) and GTTAACACTGTCGAGCACTAAAAGG (SEQ ID NO: 4)).
- An Hpal site was introduced on the side. This was cloned into a TA vector (pCR II) (pB4R + HpaI).
- the B4R gene entire region and the TA vector multi-region were converted into two types of primers (GATGCTGTTGTGCTGTGTTTGC (SEQ ID NO: 5) and TTGTGTGGAATTGTGAGCGGA (SEQ ID NO: 6)).
- the cloning site was amplified. After purification of this PCR product, both ends were blunted with T4 DNA polymerase (B4R + HpaI fragment).
- the purified genomic DNA of the m8 strain is used as a saddle, and the B6R gene is amplified by two primers (GTTAACGTTCCATAAATTGCTACCG (SEQ ID NO: 7) and GTGTGACCTCTGCGTTGAATAG (SEQ ID NO: 8)). Introduced the Hpal site. This was cloned into the TA vector (pB6R + HpaI). Concatenation of B4R and B6R
- PB6R + Hpal After confirming the base sequence of PB6R + Hpal, it was digested with Hpal and dephosphorylated with BAP. Next, it was mixed with the B4R + HpaI fragment and ligated. This mixture was made into a saddle shape, and one of the B4R and B6R genes ligated with primers ps / hr-si (TCGGAAGCAGTCGCAA CAAC (SEQ ID NO: 9)) and ps / hr-asl (ATACCATCGTCGTTAAAAGCGC (SEQ ID NO: 10)). The partial region was amplified. This PCR product was cloned into the TA vector and the nucleotide sequence was confirmed (PB4R + B6R). Construction of transfer vector (PB4R + B6R proB5RdTM) for partially deleted B5R highly expressing recombinant
- Vaccinia virus (m8 strain for m8B 5R, m8B5R for m8 ⁇ and m8p roB 5RdTM, mO strain for ⁇ and m0proB5RdTM) is cultured in RK13 cells or PK cells cultured in 80% confluent in 35 mm dishes.
- Transfer vector plasmid DNA (pB5R, m8 in the case of m8B5R), mixed with LipoiectAMINE PLUS (Invitrogen) after 1 hour of incubation at room temperature
- pB4R + B6R and in the case of m8proB5RdTM and m0proB5RdTM, PB4R + B6R proB5RdTM were added to the cells according to the manual and incorporated, and cultured at 34 for 2 days.
- the base sequence of the PCR product ⁇ ⁇ was confirmed by a direct sequence.
- a clone with no problem in the nucleotide sequence was selected and further black-purified 2 to 3 times in RK13 cells. All viruses were cultivated in large quantities in RK13 cells, purified and concentrated by ultracentrifugation using 35 (W / V)% sucrose cushion, and virus titers were measured in RK13 cells for use in experiments. .
- Figure 6 shows the construction of the virus lacking the B5R gene.
- B5R protein with the same molecular weight was confirmed in m8B5R (m8 strain with wild-type B5R gene introduced) and mO strain, and a short B5R product in the high expression type improved virus (m8proB5RdTM, m0proB5RdTM) ) ⁇ ) Confirmed. No B5R gene product was detected in m8rc (recloned m8 strain), ⁇ 8 ⁇ and ⁇ (Fig. 7a).
- the m8proB5RdTM, m0proB5RdTM, m8B5R, m0, LC16, and Wyeth strains were infected under the same culture conditions as described above, and the cultured supernatant was treated with 12.5% TCA. Concentrated with, and confirmed by Western blot (Fig. 7b). Anti-B5R Usagi polyclonal antibody was used as the primary antibody, which was detected by ECL Plus Western Blotting Detection System (Amersham Biosciences K. K.). The cell fraction was ablated 1/40 of the total, and the culture supernatant was abbreviated 1/10.
- vero cells the cells were subcultured for 2 passages, and the presence or absence of the liver was confirmed by measuring the RV content.
- the revertant content was calculated as the ratio of virus titer by vero cells to virus titer in RK13 cells.
- the recloned m8 strain (m8rc) was used as a control.
- Figure 8 shows the frequency of occurrence of revertan cocoons.
- ErD50 Eryt hema Do se 50, the amount of virus that can cause redness of 1 cm or more in 50% of the inoculated site
- m8B5R in which a wild type B5R gene was introduced into mO strain, m8 rc and m8 strain was used.
- Viruses with B5R gene activity have strong growth potential in skin and low ErD50 values (1.00, 2.25), whereas viruses lacking B5R gene (m8 rc, m8) ( ⁇ , mO ⁇ ) shows that the skin growth ability decreases and the ErD50 value increases (5.83, 5.50, 6.00), and that the B5R gene is directly related to skin growth.
- Recombinants expressing B5R lacking the TM region (m8proB 5RdTM, m0proB 5RdTM) also have a higher ErD50 value (4.75,5O) than the control virus (m8B 5R, mO) expressing wild-type B5R. 5.00), indicating that the skin growth was greatly reduced to the same extent as m8 rc, ⁇ 8 ⁇ , and mO ⁇ .
- mice Male were inoculated intraperitoneally with 10 7 to 10 9 PFU / (3ose, respectively, with m8 ⁇ , ⁇ , m8dTM, and mOdTM strains. decreased was observed the presence or absence of onset.
- Figure 1 OA and Figure 10B show weight loss in mice.
- 10 8 PFU / dose inoculation group showed some weight loss, but 10 7 PFU / dose inoculation group was similar to PBS inoculation group and MVA inoculation group There was no weight loss and no onset.
- mO, m8B5R, and Wyeth strains with B5R gene activity also started to wilch in the 10 5 PFU / dose group after 2 weeks of vaccination and started to lose weight.
- the mO-inoculated group most individuals died by 4 weeks after inoculation at any dose.
- RashEpression Dose 50 was set as the amount of virus that could cause half-individual pupae as an indicator of the pathogenicity of the virus strain to SCID mice.
- Figure 11 shows the changes over time.
- all 5 strains ⁇ 8 ⁇ , mO ⁇ , m8dTM, m0dTM, m8rc
- B5R gene function showed almost the same value, which is 21 og higher than 3 strains (m0, m8B5 Wyeth) with B5R activity. The value is shown. There was also a gap of several days at the beginning of the discovery.
- vaccinia virus is being used as a live recombinant vaccine or expression vector system in addition to its use as a pressure ulcer vaccine. It is also important for the development of acupuncture and diagnostic agents for emerging re-emerging infectious diseases. Since it can be a tool, the improvement of the m8 strain is also significant from an application perspective. All publications cited herein are hereby incorporated by reference in their entirety. Further, it will be readily understood by those skilled in the art that various modifications and variations of the present invention are possible without departing from the spirit and scope of the invention described in the appended claims. The present invention is intended to encompass such variations and modifications.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/581,495 US7638132B2 (en) | 2003-12-05 | 2003-12-05 | Highly safe smallpox vaccine virus and vaccinia virus vector |
JP2005511272A JP4719855B2 (ja) | 2003-12-05 | 2003-12-05 | 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター |
AU2003289223A AU2003289223A1 (en) | 2003-12-05 | 2003-12-05 | Highly safe smallpox vaccine virus and vaccinia virus vector |
PCT/JP2003/015632 WO2005054451A1 (ja) | 2003-12-05 | 2003-12-05 | 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター |
EP03777318A EP1710300A4 (en) | 2003-12-05 | 2003-12-05 | HIGHLY VARIATED VACCINE VIRUS AND VACCINE VIRUS VECTOR |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2003/015632 WO2005054451A1 (ja) | 2003-12-05 | 2003-12-05 | 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005054451A1 true WO2005054451A1 (ja) | 2005-06-16 |
Family
ID=34640440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/015632 WO2005054451A1 (ja) | 2003-12-05 | 2003-12-05 | 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター |
Country Status (5)
Country | Link |
---|---|
US (1) | US7638132B2 (ja) |
EP (1) | EP1710300A4 (ja) |
JP (1) | JP4719855B2 (ja) |
AU (1) | AU2003289223A1 (ja) |
WO (1) | WO2005054451A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008018411A1 (fr) * | 2006-08-07 | 2008-02-14 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Procédé de production d'un vaccin vivant antivariolique |
WO2011125469A1 (ja) * | 2010-04-09 | 2011-10-13 | 国立大学法人東京大学 | マイクロrna制御組換えワクシニアウイルス及びその使用 |
WO2012053646A1 (ja) | 2010-10-22 | 2012-04-26 | 国立大学法人北海道大学 | ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム/ブーストワクチン用ウイルスベクター |
WO2015076422A1 (ja) | 2013-11-21 | 2015-05-28 | 国立大学法人鳥取大学 | 分裂促進因子活性化タンパク質キナーゼ依存性組換えワクシニアウイルス(md-rvv)及びその使用 |
WO2020230785A1 (ja) | 2019-05-14 | 2020-11-19 | 国立大学法人鳥取大学 | 細胞融合を誘導するワクシニアウイルス及びその利用 |
US10888594B2 (en) | 2016-05-30 | 2021-01-12 | National University Corporation Tottori University | Genetically engineered vaccinia viruses |
WO2022107705A1 (ja) | 2020-11-17 | 2022-05-27 | 国立大学法人鳥取大学 | 新規遺伝子組換えワクシニアウイルス及びその利用 |
US11638730B2 (en) | 2018-09-26 | 2023-05-02 | Astellas Pharma Inc. | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5584407B2 (ja) | 2008-03-07 | 2014-09-03 | 公益財団法人東京都医学総合研究所 | C型肝炎ウイルス遺伝子を有する組換えワクシニアウイルス |
EP2873401B1 (en) | 2013-11-15 | 2017-03-01 | Hill-Rom S.A.S. | System and method for automatically adjusting the height of a patient support |
US20190336552A1 (en) * | 2016-05-30 | 2019-11-07 | Astellas Pharma Inc. | Genetically engineered vaccinia viruses |
US20210093684A1 (en) * | 2017-10-31 | 2021-04-01 | KaliVir Immunotherapeutics LLC | Platform oncolytic vector for systemic delivery |
KR20220042392A (ko) * | 2019-08-09 | 2022-04-05 | 케이엠 바이올로직스 가부시키가이샤 | 종양 용해성 백시니아 바이러스 |
IL308018A (en) | 2021-04-30 | 2023-12-01 | Kalivir Immunotherapeutics Inc | Oncolytic viruses for different MHC expression |
CN114058643A (zh) * | 2021-06-22 | 2022-02-18 | 苏州工业园区唯可达生物科技有限公司 | 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体 |
CN114058645A (zh) * | 2021-06-22 | 2022-02-18 | 苏州工业园区唯可达生物科技有限公司 | 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体 |
CN114058644A (zh) * | 2021-06-22 | 2022-02-18 | 苏州工业园区唯可达生物科技有限公司 | 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990012101A1 (en) * | 1989-04-03 | 1990-10-18 | Lynxvale Ltd. | Vaccinia vectors, vaccinia genes and expression products thereof |
JPH11509091A (ja) | 1995-07-04 | 1999-08-17 | ゲーエスエフ−フォルシュンクスツェントルム・フューア・ウムベルト・ウント・ゲズントハイト・ゲーエムベーハー | 組換えmvaウイルスおよびその使用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004087047A2 (en) * | 2003-02-07 | 2004-10-14 | Arizona Board Of Regents | Mutants of replication competent vaccinia virus |
-
2003
- 2003-12-05 US US10/581,495 patent/US7638132B2/en not_active Expired - Lifetime
- 2003-12-05 WO PCT/JP2003/015632 patent/WO2005054451A1/ja active Application Filing
- 2003-12-05 JP JP2005511272A patent/JP4719855B2/ja not_active Expired - Lifetime
- 2003-12-05 AU AU2003289223A patent/AU2003289223A1/en not_active Abandoned
- 2003-12-05 EP EP03777318A patent/EP1710300A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990012101A1 (en) * | 1989-04-03 | 1990-10-18 | Lynxvale Ltd. | Vaccinia vectors, vaccinia genes and expression products thereof |
JPH11509091A (ja) | 1995-07-04 | 1999-08-17 | ゲーエスエフ−フォルシュンクスツェントルム・フューア・ウムベルト・ウント・ゲズントハイト・ゲーエムベーハー | 組換えmvaウイルスおよびその使用 |
Non-Patent Citations (9)
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101390971B1 (ko) | 2006-08-07 | 2014-05-02 | 국립감염증연구소장이 대표하는 일본국 | 천연두 생백신의 제조방법 |
US8030020B2 (en) | 2006-08-07 | 2011-10-04 | Juridicial Foundation The Chemo-Sero-Therapeutic Research Institute | Process for preparing live smallpox vaccine |
WO2008018411A1 (fr) * | 2006-08-07 | 2008-02-14 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Procédé de production d'un vaccin vivant antivariolique |
JP5326155B2 (ja) * | 2006-08-07 | 2013-10-30 | 一般財団法人化学及血清療法研究所 | 痘瘡生ワクチンの製造方法 |
WO2011125469A1 (ja) * | 2010-04-09 | 2011-10-13 | 国立大学法人東京大学 | マイクロrna制御組換えワクシニアウイルス及びその使用 |
JP5652830B2 (ja) * | 2010-04-09 | 2015-01-14 | 国立大学法人 東京大学 | マイクロrna制御組換えワクシニアウイルス及びその使用 |
WO2012053646A1 (ja) | 2010-10-22 | 2012-04-26 | 国立大学法人北海道大学 | ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム/ブーストワクチン用ウイルスベクター |
JPWO2012053646A1 (ja) * | 2010-10-22 | 2014-02-24 | 国立大学法人北海道大学 | ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム/ブーストワクチン用ウイルスベクター |
WO2015076422A1 (ja) | 2013-11-21 | 2015-05-28 | 国立大学法人鳥取大学 | 分裂促進因子活性化タンパク質キナーゼ依存性組換えワクシニアウイルス(md-rvv)及びその使用 |
US10888594B2 (en) | 2016-05-30 | 2021-01-12 | National University Corporation Tottori University | Genetically engineered vaccinia viruses |
US11638730B2 (en) | 2018-09-26 | 2023-05-02 | Astellas Pharma Inc. | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy |
WO2020230785A1 (ja) | 2019-05-14 | 2020-11-19 | 国立大学法人鳥取大学 | 細胞融合を誘導するワクシニアウイルス及びその利用 |
WO2022107705A1 (ja) | 2020-11-17 | 2022-05-27 | 国立大学法人鳥取大学 | 新規遺伝子組換えワクシニアウイルス及びその利用 |
Also Published As
Publication number | Publication date |
---|---|
US20070298054A1 (en) | 2007-12-27 |
EP1710300A1 (en) | 2006-10-11 |
US7638132B2 (en) | 2009-12-29 |
JP4719855B2 (ja) | 2011-07-06 |
JPWO2005054451A1 (ja) | 2007-06-28 |
EP1710300A4 (en) | 2007-10-24 |
AU2003289223A1 (en) | 2005-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7113924B2 (ja) | 組み換え改変ワクシニアウイルスアンカラ(mva)フィロウイルスワクチン | |
JP3826055B2 (ja) | 組換えアビポックスウイルスによる免疫方法 | |
WO2005054451A1 (ja) | 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター | |
CN108473539B (zh) | 猫杯状病毒疫苗 | |
UA75410C2 (en) | Recombinant virus mva and use thereof | |
JP5933565B2 (ja) | 組み換え改変ワクシニアウイルスアンカラインフルエンザワクチン | |
KR101196178B1 (ko) | Hiv 조절/부속 단백질의 융합 단백질 | |
CN109789199B (zh) | 鸭肠炎病毒及其用途 | |
US20060099181A1 (en) | Viral vectors having reduced virulence | |
CN108368488B (zh) | 鸭肠炎病毒及其用途 | |
Li et al. | A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice | |
US6846652B2 (en) | Viral vectors having enhanced effectiveness with reduced virulence | |
US6372455B1 (en) | Recombinant vaccinia viral vectors | |
JP5675789B2 (ja) | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 | |
US11896658B2 (en) | RSV vaccines and methods of production and use thereof | |
JP2023545524A (ja) | 組換えhvt及びその使用 | |
KR20230022206A (ko) | 코로나바이러스 질환에 대응하는 재조합적 변형된 우두증 바이러스 앙카라 (mva) 백신 | |
JP5946453B2 (ja) | 変異狂犬病ウイルス及びワクチン | |
US20140234943A1 (en) | Viruses Lacking Epithelial Cell Receptor Entry | |
EP4316514A1 (en) | Mva-based vectors and their use as vaccine against sars-cov-2 | |
WO2022269003A1 (en) | MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN | |
JP2006121948A (ja) | 組換えウイルス | |
JPH0544269B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005511272 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10581495 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003777318 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003777318 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10581495 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10581495 Country of ref document: US |